Evidence map›Paper›PMID 35972246›Full record

ArticleMicrobiology spectrum2022

Engineered Bacteriophages Containing Anti-CRISPR Suppress Infection of Antibiotic-Resistant P. aeruginosa.

Shugang Qin, Yongan Liu, Yuting Chen, Jinrong Hu, Wen Xiao, Xiaoshan Tang, Guohong Li, Ping Lin, Qinqin Pu, Qun Wu and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Multidrug-resistantFrontiers in microbiology · 2025
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 3 countries.

Shugang Qin *Department of Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Yongan Liu *Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yuting Chen *Department of Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Jinrong HuWest China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China.
Wen XiaoDepartment of Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Xiaoshan TangDepartment of Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Guohong LiDepartment of Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Ping LinDepartment of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakotagrid.266862.e, Grand Forks, North Dakota, USA.
Qinqin PuDepartment of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakotagrid.266862.e, Grand Forks, North Dakota, USA.
Qun WuDepartment of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakotagrid.266862.e, Grand Forks, North Dakota, USA.
Chuanmin ZhouDepartment of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakotagrid.266862.e, Grand Forks, North Dakota, USA.
Biao WangDepartment of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakotagrid.266862.e, Grand Forks, North Dakota, USA.
Pan GaoDepartment of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakotagrid.266862.e, Grand Forks, North Dakota, USA.
Zhihan WangDepartment of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakotagrid.266862.e, Grand Forks, North Dakota, USA.
Aixin YanSchool of Biological Sciences, The University of Hong Konggrid.194645.b, Shatin, Hong Kong SAR.
Khan NadeemDepartment of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakotagrid.266862.e, Grand Forks, North Dakota, USA.
Zhenwei XiaDepartment of Pediatrics, Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Min WuDepartment of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakotagrid.266862.e, Grand Forks, North Dakota, USA.ORCID 0000-0003-1205-982X
University of North Dakota · USSichuan University · CNShanghai Jiao Tong University · CNChinese University of Hong Kong · HK

Funding

Research CoresP20GM103442 · NIGMS · UNIVERSITY OF NORTH DAKOTA · PI Donald A. Sens · 2012 to 2026
$53.0M
Yersina perstis interactions with macrophagesP20GM113123 · NIGMS · UNIVERSITY OF NORTH DAKOTA · PI COMBS, COLIN K · 2016 to 2025
$19.9M
Long noncoding RNAs interact with miRNAs to regulate inflammatory responseR01AI138203 · NIAID · UNIVERSITY OF NORTH DAKOTA · PI COMBS, COLIN K · 2018 to 2021
$1.4M
HHS | National Institutes of Health (NIH) AI109317-01A1NIAID NIH HHS R01 AI138203NIGMS NIH HHS P20 GM103442NIGMS NIH HHS P20 GM113123
6 · The paper itself

Abstract

The therapeutic use of bacteriophages (phages) provides great promise for treating multidrug-resistant (MDR) bacterial infections. However, an incomplete understanding of the interactions between phages and bacteria has negatively impacted the application of phage therapy. Here, we explored engineered anti-CRISPR (Acr) gene-containing phages (EATPs, eat Pseudomonas) by introducing Type I anti-CRISPR (

Indexed as

BacteriophagesPhage TherapyAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialHumansPseudomonas aeruginosaAnti-Bacterial AgentsAcranti-CRISPRbacteriophagesCRISPR-Casmultidrug resistance bacterial infectionP. aeruginosa

Identifiers

PMID35972246
PMCPMC9602763
OpenAlexW4291964160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.